Results 11 to 20 of about 6,396 (177)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case

Indian Journal of Radiology and Imaging, 2009
Arthropathy is a well known side effect of the iron chelator deferiprone (L1); however, the imaging findings in deferiprone-induced arthropathy are not well known.
Gyan Chand, Veena Chowdhury, A Manchanda, Sapna Singh   +3 more
doaj   +2 more sources

A pilot trial of deferiprone for neurodegeneration with brain iron accumulation [PDF]

Haematologica, 2011
Deferiprone was shown to reverse iron deposition in Friedreich’s ataxia. This multi-center, unblinded, single-arm pilot study evaluated safety and efficacy of deferiprone for reducing cerebral iron accumulation in neurodegeneration with brain iron ...
Giovanni Abbruzzese, Giovanni Cossu, Manuela Balocco, Roberta Marchese, Daniela Murgia, Maurizio Melis, Renzo Galanello, Susanna Barella, Gildo Matta, Uberto Ruffinengo, Ubaldo Bonuccelli, Gian Luca Forni   +11 more
doaj   +2 more sources

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

PLoS ONE, 2019
BACKGROUND:Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and
Nancy F Olivieri, Amir Sabouhanian, Brenda L Gallie   +2 more
doaj   +2 more sources

Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases [PDF]

Trends in Pharmaceutical Sciences
Thalassemia is a genetic disease that significantly affects human health. The common treatment of thalassemia is the regular injection of red blood cell, which is associated with the accumulation of iron in different tissues of the body, and makes ...
Sara Sadeghian, Fateme Zare, Lotfollah Saghaie, Razieh Sabet   +3 more
doaj   +3 more sources

Chitogel with deferiprone following endoscopic sinus surgery: improved wound healing and microbiome [PDF]

Frontiers in Surgery
BackgroundAdhesion formation, sinus ostial narrowing, and presence of pathogenic bacteria are associated with poor outcomes following endoscopic sinus surgery (ESS) for chronic rhinosinusitis.
Anna Megow, George Bouras, Yazeed Alsuliman, Clare Cooksley, Erich Vyskocil, William Murphy, Sarah Vreugde, Peter-John Wormald   +7 more
doaj   +2 more sources

Amphetamine-like Deferiprone and Clioquinol Derivatives as Iron Chelating Agents [PDF]

Molecules
The accumulation of iron in dopaminergic neurons can cause oxidative stress and dopaminergic neuron degeneration. Iron chelation therapy may reduce dopaminergic neurodegeneration, but chelators should be targeted towards dopaminergic cells. In this work,
Mahmoud El Safadi, Katie A. Wilson, Indigo J. Strudwicke, Megan L. O’Mara, Mohan Bhadbhade, Tristan Rawling, Andrew M. McDonagh   +6 more
doaj   +3 more sources

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response

Haematologica, 2012
Background Plasma non-transferrin bound iron refers to heterogeneous plasma iron species, not bound to transferrin, which appear in conditions of iron overload and ineffective erythropoiesis.
Yesim Aydinok, Patricia Evans, Chantal Y. Manz, John B. Porter   +3 more
doaj   +2 more sources

Chelator-facilitated removal of iron from transferrin: Relevance to combined chelation therapy [PDF]

, 2008
Current iron chelation therapy consists primarily of DFO (desferrioxamine), which has to be administered via intravenous infusion, together with deferiprone and deferasirox, which are orally-active chelators.
Evans, PJ, Evans, RW, Hider, RC, Devanur, LD   +3 more
core   +5 more sources

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients [PDF]

Journal of Krishna Institute of Medical Sciences University, 2015
Background: Iron overload is a predictable and lifethreatening complication in patients with thalassemia. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major.
Nargesbeygom Mirbehbahani , Azam Jahazi, Haniye Mohsenkhah Amlashi, Naser Behnampour   +3 more
doaj   +2 more sources

The therapeutic opportunities and pitfalls of using iron ion chelators to treat neurodegenerative diseases. [PDF]

FEBS Lett
Although too much iron in the brain promotes neurodegeneration, iron ion chelators have had mixed effects in clinical trials. This review explains why; some chelators do not render the iron redox‐inactive (e.g., L1) whereas others do (e.g., desferrioxamine).
Halliwell B.
europepmc   +2 more sources